Cabaletta Bio (CABA) Announces CABA-201, a Newly Designed CD19-Targeting CAR T Cell Therapy Engineered to Address a Broad Range of Autoimmune Diseases Oct 11, 2022 07:04AM
Cabaletta Bio Announces CABA-201, a Newly Designed CD19-Targeting CAR T Cell Therapy Engineered to Address a Broad Range of Autoimmune Diseases Oct 11, 2022 07:00AM
Cabaletta Bio Announces CABA-201, a Newly Designed CD19-Targeting CAR T Cell Therapy Engineered to Address a Broad Range of Autoimmune Diseases Oct 11, 2022 07:00AM
IASO Biotherapeutics and Cabaletta Bio Announce Exclusive Worldwide License Agreement for Clinically Validated CD19 Binder Oct 11, 2022 07:00AM
Cabaletta Bio (CABA) Presents New Interim Data from the DesCAARTes Trial Sep 12, 2022 05:21AM


Sep 10, 2022 07:00AM Cabaletta Bio Presents New Interim Data from the DesCAARTes™ Phase 1 Trial at the 31st EADV Congress
Sep 10, 2022 07:00AM Cabaletta Bio Presents New Interim Data from the DesCAARTes™ Phase 1 Trial at the 31st EADV Congress
Mar 23, 2022 04:00PM ROSEN, A LEADING LAW FIRM, Encourages Cabaletta Bio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CABA